Panel Discussion: Financing the Next Generation of Safer, More Effective ADCs Through Biopharma Partnerships, Collaborations & Investment Strategies
4:10 pm - Monday 8th March 2027
Discover what drives licensing decisions, investment strategies, and M&A activity, from making your ADC programmes attractive to where the next shift in the industry is heading. As large pharma companies increasingly compete for differentiated ADC platforms and clinical-stage assets, understanding the data, innovation, and risk factors behind successful deals has never been more important.
- Discussion 1 – Building the Next Wave of ADC Drugs Through Biopharma Acquisitions & Technology Scouting
- Discussion 2 – Turbocharging Biotech Innovation & Differentiation to Achieve Successful Fund Raising Rounds
